Chargement en cours...
Agomelatine in the Treatment of Major Depressive Disorder: An Assessment of Benefits and Risks
Agomelatine (AGM) was approved for the treatment of major depressive disorder (MDD) in adults by the European Medicines Agency (EMA) in February 2009. It is an analogue of melatonin and features a unique pharmacodynamic profile with agonism on both types of melatonergic receptors (MT1/MT2) and antag...
Enregistré dans:
| Publié dans: | Curr Neuropharmacol |
|---|---|
| Auteur principal: | |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Bentham Science Publishers
2014
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4243030/ https://ncbi.nlm.nih.gov/pubmed/25426008 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2174/1570159X12999140619122914 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|